The Latest Cardiac and Vascular News
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March…
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm.
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings presented at ACC.26 and simultaneously published…
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights: Announced the peer-reviewed publication in Circulation: Arrythmia and Electrophysiology, highlighting results from the U.S. Early Feasibility Study evaluating ul
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.
The partnership will provide America’s largest independent cardiovascular practice with access to AISAP’s AI-enabled cardiac diagnostic platform NEW YORK and PHILADELPHIA, March 25, 2026 /PRNewswire/ — AISAP, a pioneer in AI-powered medical diagnostics, and Cardiology Consultants of…
March 25, 2026
BETHESDA, Md.–(BUSINESS WIRE)–CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March
Microbot Medical® Strengthens LIBERTY®’s Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
